Foghorn Therapeutics (FHTX) Competitors $4.01 -0.13 (-3.16%) As of 02:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX vs. MLYS, COLL, SNDX, RCUS, ELVN, AVDL, SYRE, NTLA, PHVS, and ARDXShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Mineralys Therapeutics (MLYS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Arcus Biosciences (RCUS), Enliven Therapeutics (ELVN), Avadel Pharmaceuticals (AVDL), Spyre Therapeutics (SYRE), Intellia Therapeutics (NTLA), Pharvaris (PHVS), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. Mineralys Therapeutics Collegium Pharmaceutical Syndax Pharmaceuticals Arcus Biosciences Enliven Therapeutics Avadel Pharmaceuticals Spyre Therapeutics Intellia Therapeutics Pharvaris Ardelyx Foghorn Therapeutics (NASDAQ:FHTX) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, community ranking, valuation, earnings, risk, dividends, profitability and analyst recommendations. Is FHTX or MLYS more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-357.53% N/A -30.98% Mineralys Therapeutics N/A -67.97%-62.40% Which has stronger valuation & earnings, FHTX or MLYS? Foghorn Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$22.60M10.09-$98.43M-$1.36-3.01Mineralys TherapeuticsN/AN/A-$177.81M-$3.73-4.34 Do analysts prefer FHTX or MLYS? Foghorn Therapeutics presently has a consensus price target of $12.13, indicating a potential upside of 196.45%. Mineralys Therapeutics has a consensus price target of $38.00, indicating a potential upside of 134.71%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Foghorn Therapeutics is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.13Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer FHTX or MLYS? Foghorn Therapeutics received 27 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 95.24% of users gave Mineralys Therapeutics an outperform vote while only 66.20% of users gave Foghorn Therapeutics an outperform vote. CompanyUnderperformOutperformFoghorn TherapeuticsOutperform Votes4766.20% Underperform Votes2433.80% Mineralys TherapeuticsOutperform Votes2095.24% Underperform Votes14.76% Do insiders & institutionals have more ownership in FHTX or MLYS? 61.5% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to FHTX or MLYS? In the previous week, Mineralys Therapeutics had 4 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 17 mentions for Mineralys Therapeutics and 13 mentions for Foghorn Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.83 beat Foghorn Therapeutics' score of 0.05 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, FHTX or MLYS? Foghorn Therapeutics has a beta of 3.13, indicating that its stock price is 213% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500. SummaryFoghorn Therapeutics beats Mineralys Therapeutics on 12 of the 18 factors compared between the two stocks. Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$227.98M$6.54B$5.40B$8.49BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-2.139.1826.7119.93Price / Sales10.09256.43395.44119.84Price / CashN/A65.8538.2534.62Price / Book-2.236.536.854.59Net Income-$98.43M$144.00M$3.23B$248.19M7 Day Performance-0.49%5.01%5.35%2.21%1 Month Performance4.87%9.58%13.31%16.23%1 Year Performance-34.24%-0.94%17.58%8.00% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.689 of 5 stars$4.01-3.2%$12.13+202.4%-31.0%$223.47M$22.60M-2.09120News CoverageEarnings ReportAnalyst RevisionGap DownMLYSMineralys Therapeutics2.7745 of 5 stars$15.01+2.5%$33.00+119.9%+25.7%$973.79MN/A-4.1228Gap DownCOLLCollegium Pharmaceutical4.113 of 5 stars$29.56+2.3%$43.80+48.2%-12.3%$949.82M$631.45M12.74210News CoverageGap UpSNDXSyndax Pharmaceuticals3.8837 of 5 stars$10.99+2.7%$35.91+226.7%-47.8%$945.66M$43.72M-3.03110Positive NewsRCUSArcus Biosciences3.5937 of 5 stars$8.82+6.5%$25.67+191.2%-47.4%$933.38M$141M-2.80500Gap UpHigh Trading VolumeELVNEnliven Therapeutics2.534 of 5 stars$19.01+3.2%$40.33+112.2%-27.6%$932.75MN/A-10.0150Earnings ReportAnalyst RevisionAVDLAvadel Pharmaceuticals2.2395 of 5 stars$9.59+2.1%$19.43+102.6%-40.3%$926.67M$169.12M-12.1470Positive NewsSYRESpyre Therapeutics2.3533 of 5 stars$14.93+5.9%$51.17+242.7%-58.2%$899.92M$890,000.00-2.00100Positive NewsGap DownNTLAIntellia Therapeutics4.668 of 5 stars$8.55+5.3%$36.90+331.6%-62.6%$885.64M$57.88M-1.57600Analyst ForecastPHVSPharvaris1.2946 of 5 stars$16.81-1.1%$41.67+147.9%-16.5%$879.00MN/A-6.0030ARDXArdelyx4.5525 of 5 stars$3.53-2.5%$10.39+194.3%-47.3%$844.57M$361.71M-22.0690Insider Trade Related Companies and Tools Related Companies Mineralys Therapeutics Competitors Collegium Pharmaceutical Competitors Syndax Pharmaceuticals Competitors Arcus Biosciences Competitors Enliven Therapeutics Competitors Avadel Pharmaceuticals Competitors Spyre Therapeutics Competitors Intellia Therapeutics Competitors Pharvaris Competitors Ardelyx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FHTX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FHTX Stock Free FHTX Stock Alerts